Coeptis Therapeutics (NASDAQ:ZSQR) Trading Down 6.3% – What’s Next?

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR)’s stock price was down 6.3% on Monday . The company traded as low as $11.67 and last traded at $11.67. Approximately 397,179 shares were traded during mid-day trading, an increase of 106% from the average daily volume of 192,465 shares. The stock had previously closed at $12.46.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen cut shares of Coeptis Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Coeptis Therapeutics Stock Down 2.2%

The company has a quick ratio of 3.25, a current ratio of 3.25 and a debt-to-equity ratio of 0.01. The company has a fifty day simple moving average of $12.24 and a 200 day simple moving average of $12.68. The firm has a market capitalization of $532.30 million, a P/E ratio of -4.11 and a beta of -0.22.

Coeptis Therapeutics (NASDAQ:ZSQR) last released its earnings results on Thursday, May 14th. The company reported ($0.65) EPS for the quarter. Coeptis Therapeutics had a negative return on equity of 92.29% and a negative net margin of 810.04%.The company had revenue of $0.11 million during the quarter.

Institutional Investors Weigh In On Coeptis Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Yorkville Advisors Global LP purchased a new stake in Coeptis Therapeutics during the 3rd quarter valued at $140,000. Geode Capital Management LLC lifted its stake in Coeptis Therapeutics by 12.6% during the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after acquiring an additional 4,721 shares during the period. Steward Partners Investment Advisory LLC boosted its holdings in shares of Coeptis Therapeutics by 100.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after acquiring an additional 2,500 shares during the last quarter. State Street Corp boosted its holdings in shares of Coeptis Therapeutics by 35.0% during the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock valued at $382,000 after acquiring an additional 6,962 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Coeptis Therapeutics in the fourth quarter worth approximately $259,000. Institutional investors own 13.88% of the company’s stock.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.